OKYO Pharma Ltd ADR Total Assets
OKYO Pharma Ltd ADR total assets. Based on the latest financial reports, OKYO Pharma Ltd ADR (OKYO) holds total assets worth $20.98 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see OKYO Pharma Ltd ADR market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of OKYO Pharma Ltd ADR (2008–2026)
Total assets of OKYO Pharma Ltd ADR from 2008 to 2026. This chart illustrates how OKYO Pharma Ltd ADR's total assets have evolved over time, based on quarterly financial data. See current stock price of OKYO Pharma Ltd ADR for real-time trading data and today's change.
OKYO Pharma Ltd ADR - Asset Composition Analysis
OKYO Pharma Ltd ADR Total Assets Breakdown (March 2026)
OKYO Pharma Ltd ADR total assets breakdown as of March 2026. OKYO Pharma Ltd ADR's total assets of $20.98 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 69.6% |
| Accounts Receivable | $170.67K | 0.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2026)
This chart illustrates how OKYO Pharma Ltd ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore OKYO current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OKYO Pharma Ltd ADR's current assets represent 100.0% of total assets in 2026, an increase from 65.4% in 2008.
- Cash Position: Cash and equivalents constituted 69.6% of total assets in 2026, up from 65.1% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 0.8% of total assets.
OKYO Pharma Ltd ADR Competitors by Total Assets
Key competitors of OKYO Pharma Ltd ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
OKYO Pharma Ltd ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.43 | 0.40 | 4.09 |
| Quick Ratio | 2.43 | 0.40 | 4.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $12.33 Million | $-5.55 Million | $956.29K |
OKYO Pharma Ltd ADR - Advanced Valuation Insights
This section examines the relationship between OKYO Pharma Ltd ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.17 |
| Latest Market Cap to Assets Ratio | 2.85 |
| Asset Growth Rate (YoY) | 470.4% |
| Total Assets | $20.98 Million |
| Market Capitalization | $59.80 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values OKYO Pharma Ltd ADR's assets at a significant premium (2.85x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: OKYO Pharma Ltd ADR's assets grew by 470.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for OKYO Pharma Ltd ADR (2008–2026)
The table below shows the annual total assets of OKYO Pharma Ltd ADR from 2008 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | $20.98 Million | +470.42% |
| 2025-03-31 | $3.68 Million | +138.59% |
| 2024-03-31 | $1.54 Million | -70.38% |
| 2023-03-31 | $5.20 Million | +21.00% |
| 2022-03-31 | $4.30 Million | -39.35% |
| 2021-03-31 | $7.09 Million | +1087.03% |
| 2020-03-31 | $597.40K | -21.38% |
| 2019-03-31 | $759.86K | -62.16% |
| 2018-03-31 | $2.01 Million | -92.77% |
| 2017-03-31 | $27.76 Million | -13.76% |
| 2016-03-31 | $32.18 Million | -5.47% |
| 2015-03-31 | $34.05 Million | -27.88% |
| 2014-03-31 | $47.21 Million | +4.45% |
| 2013-03-31 | $45.20 Million | +7.11% |
| 2012-03-31 | $42.20 Million | +162.25% |
| 2011-03-31 | $16.09 Million | -70.28% |
| 2010-03-31 | $54.13 Million | +41.46% |
| 2009-03-31 | $38.27 Million | +38.64% |
| 2008-03-31 | $27.60 Million | -- |
About OKYO Pharma Ltd ADR
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to t… Read more